Trelagliptin in the Treatment of Patients with Type 2 Diabetes Mellitus - Efficacy and Safety

Abstract

This article discusses the efficacy and safety of Vedic 100 mg (trelagliptin) in patients with type 2 diabetes mellitus (DM). The drug belongs to the group of DPP-4 inhibitors, to be taken once a week. This drug controls blood glucose levels by selectively and permanently inhibiting DPP-4, an enzyme that causes the inactivation of glucagon-like peptide-1 and glucagon-dependent insulinotropic polypeptide, incretin hormones that play an important role in the regulation of blood glucose levels. The drug was taken in combination with metformin for a month. The drug was prescribed to patients (n-24) with type 2 diabetes, with a glycated hemoglobin of 7-9%, who were on metformin monotherapy before the study. Trelagliptin 100 mg was added to metformin once a week. The results showed that the drug has a positive effect on the main metabolic disorders of DM and allows achieving compensation of carbohydrate metabolism, as indicated by a decrease in fasting glycemia by 20% (p<0.05), postprandial glycemia by 18% and glycated hemoglobin by 16%. Improvements in lipid metabolism were also noted. However, none of the patients experienced hypoglycemia.